• +1-646-491-9876
    • +91-20-67278686

    Search

    Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2017

    Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2017

    • Report Code ID: RW0001689406
    • Category Healthcare
    • No. of Pages 135
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2017, provides an overview of the Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline landscape.

    Post-traumatic stress disorder (PTSD) is a mental health condition that's triggered by a terrifying event either experiencing it or witnessing it. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants, anti-anxiety and cognitive therapy.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Traumatic Stress Disorder (PTSD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 3, 17 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 7 and 1 molecules, respectively.

    Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
    - The pipeline guide reviews pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Post-Traumatic Stress Disorder (PTSD) - Overview
    Post-Traumatic Stress Disorder (PTSD) - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Post-Traumatic Stress Disorder (PTSD) - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Post-Traumatic Stress Disorder (PTSD) - Companies Involved in Therapeutics Development
    Addex Therapeutics Ltd
    Amorsa Therapeutics Inc
    Azevan Pharmaceuticals Inc
    Bionomics Ltd
    Catalyst Pharmaceuticals Inc
    Cerecor Inc
    Chronos Therapeutics Ltd
    Corcept Therapeutics Inc
    Eli Lilly and Company
    Embera NeuroTherapeutics Inc
    Intra-Cellular Therapies Inc
    INVENT Pharmaceuticals Inc
    Marinus Pharmaceuticals Inc
    Neuralstem Inc
    NeuroNascent Inc
    Omeros Corp
    Otsuka Holdings Co Ltd
    Pragma Therapeutics SAS
    Synchroneuron Inc
    Tonix Pharmaceuticals Holding Corp
    TRImaran Pharma Inc
    Post-Traumatic Stress Disorder (PTSD) - Drug Profiles
    (metyrapone + oxazepam) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    acamprosate calcium SR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ADX-71743 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AM-3506 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BNC-210 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    brexpiprazole - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CERC-501 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CPP-115 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CTDP-003 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    D-473 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ganaxolone - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IC-87201 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    INV-107 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KDAC-0001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    lumateperone tosylate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    midomafetamine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    modafinil - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NNI-351 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NSI-189 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PGT-117 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Rycal - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Target GPR83 for CNS and Immunological Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Agonize EP1 for Post-Traumatic Stress Disorder - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Agonize Nociceptin Receptor for Post Traumatic Stress Disorder - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Antagonize Glucocorticoid Receptor II for Post Traumatic Stress Disorder - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Antagonize mGluR7 for Central Nervous System Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Target NMDA Receptor for Post-Traumatic Stress Disorder - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SRX-246 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptide to Antagonize EPHA4 for Post-Traumatic Stress Disorder - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptide to Target NPSR for Anxiety Disorder - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tianeptine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TNX-102 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine for CNS Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ZL-006 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Post-Traumatic Stress Disorder (PTSD) - Dormant Projects
    Post-Traumatic Stress Disorder (PTSD) - Discontinued Products
    Post-Traumatic Stress Disorder (PTSD) - Product Development Milestones
    Featured News & Press Releases
    Feb 09, 2017: Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at the 2017 BIO CEO & Investor Conference
    Jan 24, 2017: Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at NobleCon13
    Jan 10, 2017: Tonix Pharmaceuticals Provides Update on TNX-601 at 9th Annual Biotech Showcase Conference
    Jan 10, 2017: Tonix Pharmaceuticals Provides Update on TNX-102 at 9th Annual Biotech Showcase Conference
    Jan 05, 2017: Marinus Provides Business Outlook for 2017
    Jan 03, 2017: Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at 9th Annual Biotech Showcase Conference
    Dec 19, 2016: Tonix Pharmaceuticals' PTSD Phase 3-Ready Drug Candidate, TNX-102 SL, Granted Breakthrough Therapy Designation by the FDA
    Dec 08, 2016: Tonix Pharmaceuticals Presented New Clinical Results from Sub-Group Analysis of Phase 2 AtEase Study in Military-Related Posttraumatic Stress Disorder
    Dec 02, 2016: Tonix Pharmaceuticals to Present Clinical Data at the 55th Annual Meeting of the American College of Neuropsychopharmacology (ACNP)
    Nov 10, 2016: Tonix Pharmaceuticals to Present New Clinical Results from Retrospective Analysis of Phase 2 AtEase Study in Military-Related PTSD
    Nov 07, 2016: Tonix Pharmaceuticals to Present Clinical Data at the International Society for Traumatic Stress Studies (ISTSS) 32nd Annual Meeting
    Nov 02, 2016: Tonix Pharmaceuticals to Present at 22nd Annual BIO-Europe International Partnering Conference
    Nov 01, 2016: Tonix Pharmaceuticals to Present Clinical Data at the 2016 Neuroscience Education Institute (NEI) Psychopharmacology Congress
    Oct 27, 2016: Tonix Pharmaceuticals to Present Clinical Data at CNS Summit 2016
    Sep 16, 2016: Bionomics to present anti-anxiety drug treatment trial results and ADHD treatment research at ECNP
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Post-Traumatic Stress Disorder (PTSD) - Pipeline by Addex Therapeutics Ltd, H1 2017
    Post-Traumatic Stress Disorder (PTSD) - Pipeline by Amorsa Therapeutics Inc, H1 2017
    Post-Traumatic Stress Disorder (PTSD) - Pipeline by Azevan Pharmaceuticals Inc, H1 2017
    Post-Traumatic Stress Disorder (PTSD) - Pipeline by Bionomics Ltd, H1 2017
    Post-Traumatic Stress Disorder (PTSD) - Pipeline by Catalyst Pharmaceuticals Inc, H1 2017
    Post-Traumatic Stress Disorder (PTSD) - Pipeline by Cerecor Inc, H1 2017
    Post-Traumatic Stress Disorder (PTSD) - Pipeline by Chronos Therapeutics Ltd, H1 2017
    Post-Traumatic Stress Disorder (PTSD) - Pipeline by Corcept Therapeutics Inc, H1 2017
    Post-Traumatic Stress Disorder (PTSD) - Pipeline by Eli Lilly and Company, H1 2017
    Post-Traumatic Stress Disorder (PTSD) - Pipeline by Embera NeuroTherapeutics Inc, H1 2017
    Post-Traumatic Stress Disorder (PTSD) - Pipeline by Intra-Cellular Therapies Inc, H1 2017
    Post-Traumatic Stress Disorder (PTSD) - Pipeline by INVENT Pharmaceuticals Inc, H1 2017
    Post-Traumatic Stress Disorder (PTSD) - Pipeline by Marinus Pharmaceuticals Inc, H1 2017
    Post-Traumatic Stress Disorder (PTSD) - Pipeline by Neuralstem Inc, H1 2017
    Post-Traumatic Stress Disorder (PTSD) - Pipeline by NeuroNascent Inc, H1 2017
    Post-Traumatic Stress Disorder (PTSD) - Pipeline by Omeros Corp, H1 2017
    Post-Traumatic Stress Disorder (PTSD) - Pipeline by Otsuka Holdings Co Ltd, H1 2017
    Post-Traumatic Stress Disorder (PTSD) - Pipeline by Pragma Therapeutics SAS, H1 2017
    Post-Traumatic Stress Disorder (PTSD) - Pipeline by Synchroneuron Inc, H1 2017
    Post-Traumatic Stress Disorder (PTSD) - Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2017
    Post-Traumatic Stress Disorder (PTSD) - Pipeline by TRImaran Pharma Inc, H1 2017
    Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H1 2017
    Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H1 2017 (Contd..1), H1 2017
    Post-Traumatic Stress Disorder (PTSD) - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Addex Therapeutics Ltd
    Amorsa Therapeutics Inc
    Azevan Pharmaceuticals Inc
    Bionomics Ltd
    Catalyst Pharmaceuticals Inc
    Cerecor Inc
    Chronos Therapeutics Ltd
    Corcept Therapeutics Inc
    Eli Lilly and Company
    Embera NeuroTherapeutics Inc
    Intra-Cellular Therapies Inc
    INVENT Pharmaceuticals Inc
    Marinus Pharmaceuticals Inc
    Neuralstem Inc
    NeuroNascent Inc
    Omeros Corp
    Otsuka Holdings Co Ltd
    Pragma Therapeutics SAS
    Synchroneuron Inc
    Tonix Pharmaceuticals Holding Corp
    TRImaran Pharma Inc

    Request for Sample

    Report Url http://www.reportsweb.com//post-traumatic-stress-disorder-ptsd-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//post-traumatic-stress-disorder-ptsd-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//post-traumatic-stress-disorder-ptsd-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments